The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain
- 186 Downloads
The surface bone-seeking radiopharmaceuticals rhenium-188-HEDP (188Re-HEDP) and samarium-153-EDTMP (153Sm-EDTMP) were investigated to determine the efficacy and toxicity in pain palliation in bone metastases.
The effect of treatment with 188Re-HEDP and 153Sm-EDTMP on pain symptoms, life quality, and bone marrow function were obtained in 46 patients with prostate and breast cancer. There were 31 patients treated with 188Re-HEDP (3194±387 MBq) and 15 patients with 153Sm-EDTMP (2940±545 MBq). The 188Re-HEDP group included 6 patients and 25 patients, and the 153Sm-EDTMP group 6 patients and 9 patients with breast and prostate cancer, respectively. All patients had an interview using standardized sets of questions before and after therapy for 12 weeks. Blood counts were taken weekly for 6 weeks and after 12 weeks.
After treatment with 188Re-HEDP, 77% of patients reported pain relief and 73% after 153Sm-EDTMP. Sixteen percent of the patients treated with 188Re-HEDP and 13% of those given 153Sm-EDTMP could discontinue their analgesics and were pain free. Patients described an improvement on the Karnofsky performance scale from 73±7 to 85±8% 12 weeks after 188Re-HEDP (p<0.05) and from 68±9 to 74±9% after 153Sm-EDTMP (p=0.217). Only 3 patients post-188Re-HEDP and 2 patients post-153Sm-EDTMP showed a thrombocytopenia below 100×103/µl. The maximum nadir of platelet and leukocyte counts were observed between the second to fourth week after treatment in both and was reversible within 12 weeks. There were no significant differences in pain palliation, Karnofsky performance scale and bone marrow toxicity between the lower beta energy 153Sm-EDTMP and the higher beta energy 188Re-HEDP (p=0.098–0.442).
Both radiopharmaceuticals were effective in pain palliation, without induction of severe side effects or significant differences in therapeutic efficacy or toxicity.
Keywords188Re-HEDP 153Sm-EDTMP Bone palliation Breast cancer Prostate cancer
- Blower PJ, Kettle AG, O’Doherty MJ, Coakley AJ, Knapp FF Jr (2000) 99mTc(V)DMSA quantitatively predicts 188Re(V)DMSA distribution in patients with prostate cancer metastatic to bone. Eur J Nucl Med 27:1405–1409Google Scholar
- Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, De Conno F (2002) Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 23:239–255CrossRefPubMedGoogle Scholar
- Eisenhut M, Berberich R, Kimmig B, Oberhausen E (1986) Iodine-131-labeled diphosphonates for palliative treatment of bone metastases. II. Preliminary clinical results with iodine-131 BDP3. J Nucl Med 27:1255–1261Google Scholar
- Enrique O, Zhonyun P, Prma EP, Pusuwan P, Ricobona G, Tian JH, Obaldo J, Padhy AK (2002) Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases. World J Nucl Med 1:21–27Google Scholar
- Friedell HL, Storaasli JP (1950) The use of radioactive phosphorus in treatment of carcinoma of the breast with widespread metastasis in bone. AJR 64:559–575Google Scholar
- Lin WY, Lin CP, Yeh SJ, Hsieh BT, Tsai ZT, Ting G, Yen TC, Wang SJ, Knapp FF Jr, Stabin MG (1997) Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur J Nucl Med 24:590–595CrossRefPubMedGoogle Scholar
- Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grunwald F, Knapp FF Jr, Biersack HJ (2000) Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 27:123–130Google Scholar
- Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF Jr. et al. (2003) Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 21:2869–2875CrossRefPubMedGoogle Scholar
- Pecher P (1942) Biological investigation with radioactive calcium and strontium. Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Univ Calif Publ Pharmacol 2:117–149Google Scholar
- Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D (1997) A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33:1583–1591CrossRefPubMedGoogle Scholar
- Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ (1999) Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 26:2–7CrossRefPubMedGoogle Scholar
- Turner JH, Claringbold PG (1991) A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 27:1084–1086Google Scholar
- World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment (Geneva, Switzerland)Google Scholar